Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Phase Ib of pembrolizumab (pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MMR-proficient (pMMR) colorectal cancer (CRC): Final results.
Authors
Dustin A. Deming
University of Wisconsin Carbone Cancer Center, Madison, WI;
Dustin A. Deming , Sam Joseph Lubner , Nataliya Volodymyrivna Uboha , Philip Emmerich , Sean Kraus , Noelle K. LoConte , David H. Kim , Kristina A. Matkowskyj , Sharon Weber , Daniel Abbott , Jens C. Eickhoff , Michael F. Bassetti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02837263
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 161)
DOI
10.1200/JCO.2023.41.4_suppl.161
Abstract #
161
Poster Bd #
H20
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver oligometastatic MSS/MMR proficient colorectal cancer (CRC).
First Author: Dustin A. Deming
Poster
2019 Gastrointestinal Cancers Symposium
A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC).
First Author: Anita Ahmed Turk
Poster
2018 Gastrointestinal Cancers Symposium
Keynote 290: Pembrolizumab (pem) in combination with stereotactic body radiotherapy for resectable liver metastatic colorectal cancer.
First Author: Dustin A. Deming
Poster
2021 Gastrointestinal Cancers Symposium
Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.
First Author: Marwan Fakih